drugset / Trial / NCT01291511

Relapse Prevention Study in Patients With Schizophrenia

NCT01291511

Phase 3 Completed 635 enrolled Vanda Pharmaceuticals
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to determine whether Iloperidone is effective in the prevention of relapse in patients with schizophrenia

Timeline

Start
2011-02
Primary completion
2014-03
Completion
2015-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Iloperidone Small molecule 12 mg Oral

Indications